Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,734 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,061 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | active not recruiting | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Feb 24, 2026 |
| clinicaltrials |
| NCT06356597 | Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial | active not recruiting | Phase 2 | 33 | Jing-yuan Fang, MD, Ph. DOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT00548236 | The Active After Cancer Trial (AACT)(AACT) | active not recruiting | N/A | 120 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05587972 | Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring | active not recruiting | N/A | 100 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03523546 | Oncology Episode Payment Model in Hawaii | active not recruiting | N/A | 7 | University of PennsylvaniaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05927298 | Province of Ontario Strategy for Personalized Management of Pancreatic Cancer Trial(ProsperPanc) | active not recruiting | — | 200 | University Health Network, TorontoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | active not recruiting | Phase 1 / Phase 2 | 194 | Merus B.V.INDUSTRY | 9 | Feb 19, 2026 | clinicaltrials |
| NCT05171660 | Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 446 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07412301 | The Effect of Celiac Axis Stenosis on Morbidity After Pancreatoduodenectomy - A Prospective Study | active not recruiting | — | 99 | Larissa University HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05466799 | FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma(TRIPP-FFX) | active not recruiting | Phase 2 | 88 | OncoSil Medical LimitedINDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT01460589 | Early Commencement of Adjuvant Chemotherapy for Colon Cancer(ECTX) | active not recruiting | Phase 3 | 303 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05673772 | Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer(SOLAR) | active not recruiting | Phase 2 | 364 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03426904 | Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer | active not recruiting | Phase 3 | 708 | Kyungpook National University HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07403916 | Influence of Age on the Choice of Treatment and Prognosis in Patients With Resectable Gastric Cancer | active not recruiting | — | 90 | P. Herzen Moscow Oncology Research InstituteOTHER_GOV | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06023004 | The Diverticulitis Study | active not recruiting | — | 250 | University of AarhusOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01815359 | ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis(ICARuS) | active not recruiting | Phase 2 | 292 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02531607 | Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC) | active not recruiting | — | 500 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02967848 | Liver Function Investigation With SPECT(LiverINSPECT) | active not recruiting | — | 20 | Royal North Shore HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06268015 | Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo) | active not recruiting | Phase 2 | 16 | Nicholas DeVito, MDOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02336087 | Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery | active not recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04736121 | Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients(DOORwaY90) | active not recruiting | N/A | 100 | Sirtex MedicalINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04762953 | Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis(STOPGAP) | active not recruiting | Phase 2 | 40 | University of California, IrvineOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07380633 | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | active not recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03615599 | Plant-based Diets and Risk of Cancer in the Adventist Health Study-2(AHS-2) | active not recruiting | — | 96,000 | Loma Linda UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04854668 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 748 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01918683 | TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | active not recruiting | N/A | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05113186 | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative(LENVABLA) | active not recruiting | Phase 2 | 32 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06688786 | A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer(FIRM) | active not recruiting | N/A | 30 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04005339 | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | active not recruiting | Phase 2 | 48 | Georgetown UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04137107 | Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 220 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jan 26, 2026 | clinicaltrials |
| NCT05634720 | Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | active not recruiting | Phase 4 | 20 | Duke UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04781192 | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | active not recruiting | Phase 1 / Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05210322 | Percutaneous Cholangiopancreatoscopy Registry | active not recruiting | — | 679 | Johns Hopkins UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362264 | A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04377932 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04767984 | Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis | active not recruiting | Phase 2 | 42 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | active not recruiting | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05327452 | Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study | active not recruiting | N/A | 135 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05708599 | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | active not recruiting | N/A | 102 | Boehringer IngelheimINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Feb 24, 2026source: clinicaltrials